Oakbrook Investments LLC cut its holdings in shares of Eli Lilly And Co (NYSE:LLY) by 7.7% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 43,650 shares of the company’s stock after selling 3,625 shares during the quarter. Oakbrook Investments LLC’s holdings in Eli Lilly And Co were worth $4,881,000 as of its most recent SEC filing.
A number of other institutional investors have also added to or reduced their stakes in LLY. Enterprise Trust & Investment Co acquired a new stake in shares of Eli Lilly And Co in the 3rd quarter valued at $27,000. Prestige Wealth Management Group LLC acquired a new stake in Eli Lilly And Co during the 2nd quarter worth $34,000. Manchester Financial Inc. acquired a new stake in Eli Lilly And Co during the 2nd quarter worth $40,000. Litman Gregory Asset Management LLC acquired a new stake in Eli Lilly And Co during the 2nd quarter worth $47,000. Finally, Asset Dedication LLC raised its stake in Eli Lilly And Co by 372.9% during the 3rd quarter. Asset Dedication LLC now owns 454 shares of the company’s stock worth $52,000 after acquiring an additional 358 shares in the last quarter. Institutional investors own 77.22% of the company’s stock.
LLY traded up $0.76 during midday trading on Friday, reaching $113.53. 2,190,598 shares of the company’s stock were exchanged, compared to its average volume of 7,683,282. The business’s 50-day moving average price is $110.61 and its 200 day moving average price is $112.67. The company has a debt-to-equity ratio of 4.09, a current ratio of 1.17 and a quick ratio of 0.88. The stock has a market capitalization of $106.81 billion, a PE ratio of 20.46, a P/E/G ratio of 1.82 and a beta of 0.16. Eli Lilly And Co has a 1-year low of $101.36 and a 1-year high of $132.13.
Eli Lilly And Co (NYSE:LLY) last posted its quarterly earnings data on Wednesday, October 23rd. The company reported $1.48 earnings per share for the quarter, beating analysts’ consensus estimates of $1.43 by $0.05. The business had revenue of $5.48 billion during the quarter, compared to analyst estimates of $5.50 billion. Eli Lilly And Co had a net margin of 35.10% and a return on equity of 107.99%. The company’s revenue was up 3.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.39 earnings per share. As a group, analysts expect that Eli Lilly And Co will post 5.78 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be issued a $0.645 dividend. The ex-dividend date is Thursday, November 14th. This represents a $2.58 dividend on an annualized basis and a yield of 2.27%. Eli Lilly And Co’s payout ratio is 46.49%.
In other Eli Lilly And Co news, CEO David A. Ricks acquired 4,615 shares of the firm’s stock in a transaction on Friday, October 25th. The stock was bought at an average cost of $108.38 per share, for a total transaction of $500,173.70. Following the completion of the purchase, the chief executive officer now directly owns 157,405 shares in the company, valued at $17,059,553.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Lilly Endowment Inc sold 173,918 shares of the business’s stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $114.05, for a total transaction of $19,835,347.90. Following the sale, the insider now owns 116,229,383 shares of the company’s stock, valued at $13,255,961,131.15. The disclosure for this sale can be found here. Over the last 90 days, insiders purchased 8,405 shares of company stock valued at $909,004 and sold 614,373 shares valued at $70,546,895. 0.11% of the stock is currently owned by insiders.
Several brokerages recently commented on LLY. Bank of America started coverage on shares of Eli Lilly And Co in a research note on Wednesday, October 16th. They set a “buy” rating and a $133.00 price target on the stock. UBS Group lowered their price objective on shares of Eli Lilly And Co from $134.00 to $133.00 and set a “buy” rating on the stock in a research report on Thursday, October 17th. Six analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $130.03.
Eli Lilly And Co Company Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Read More: What Does a Sell-Side Analyst Rating Mean?
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.